Blockchain Registration Transaction Record

Quantum BioPharma's Lucid-MS Targets Myelin to Halt Multiple Sclerosis

Quantum BioPharma's Lucid-MS, a patented drug candidate targeting myelin repair, enters phase 2 trials for MS. Learn how this novel approach could halt disease progression.

This news matters because MS affects millions without a cure, and current treatments only slow progression. Quantum BioPharma's Lucid-MS offers a novel approach that could potentially halt the disease by targeting myelin repair, addressing a critical unmet need. If successful in phase 2 trials, it could change the treatment paradigm, offering patients hope for stopping disability progression rather than just managing symptoms.